GTx-758

GTx-758
Clinical data
Other names	Capesaris
Routes of; administration	By mouth
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name 3-fluoro-N-(4-fluorophenyl)-4-hydroxy-N-(4-hydroxyphenyl)benzamide;
CAS Number	938067-78-8;
PubChem CID	46861578;
ChemSpider	34954411;
UNII	406GR1485Z;
ChEMBL	ChEMBL3545017;
Chemical and physical data
Formula	C19H13F2NO3
Molar mass	341.314 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=CC=C1N(C2=CC=C(C=C2)F)C(=O)C3=CC(=C(C=C3)O)F)O;
	InChI InChI=1S/C19H13F2NO3/c20-13-2-4-14(5-3-13)22(15-6-8-16(23)9-7-15)19(25)12-1-10-18(24)17(21)11-12/h1-11,23-24H; Key:FBCQEUMZZNVQKD-UHFFFAOYSA-N;

GTx-758 (tentative brand name Capesaris) is a synthetic nonsteroidal estrogen which was under development by GTx, Inc. for the treatment of advanced prostate cancer. As of 2016, it had completed two phase II clinical trials.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.